Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology NEW YORK , Oct.
Seeking Alpha: Oramed oral COVID vaccine shows promise in phase 1 trial
Oramed oral COVID vaccine shows promise in phase 1 trial | Seeking Alpha
